Adverse events in each therapy group
| Adverse event | VA-dual (n=168) | VAC-triple (n=167) | P value |
| Diarrhoea | 16 (9.5%) | 25 (15.0%) | 0.128 |
| Moderate | 1 | 3 | |
| Bloating | 20 (11.9%) | 14 (8.4%) | 0.286 |
| Moderate | 1 | 0 | |
| Constipation | 10 (6.0%) | 8 (4.8%) | 0.637 |
| Skin rash | 9 (5.4%) | 5 (3.0%) | 0.280 |
| Moderate | 4 | 1 | |
| Nausea | 5 (3.0%) | 4 (2.4%) | 0.742 |
| Moderate | 0 | 1 | |
| Abdominal pain | 6 (3.6%) | 2 (1.2%) | 0.155 |
| Moderate | 1 | 0 | |
| Dysgeusia | 3 (1.8%) | 3 (1.8%) | 0.994 |
| Oral mucositis | 0 | 6 (3.6%) | 0.013 |
| Others | 2 (1.2%) | 2 (1.2%) | 0.995 |
| Total patients | 46 (27.4%) | 51 (30.5%) | 0.524 |
VAC-triple, vonoprazan, amoxicillin and clarithromycin triple therapy; VA-dual, vonoprazan and amoxicillin dual therapy.